Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 8, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the LEERINK Partners 7^th Annual Global Healthcare Conference in New York, NY.  The presentation is scheduled for Thursday, February 15, 2018, at 10:30 am ET.

To access a live webcast of the presentation, please visit the Events & Presentations page within the Investors + Media section of the Audentes website.  A replay of the live webcast will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We are currently conducting a Phase 1/2 clinical study of our lead product candidate AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) and have three additional product candidates in development, including AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
[email protected]

Media Contact:
Paul Laland
415.519.6610
[email protected]

SOURCE Audentes Therapeutics, Inc.

Related Links

https://www.audentestx.com